Understanding the Pre-IDE Program: FDA Perspective

Slides:



Advertisements
Similar presentations
BME-IDEA Workshop, September 28, 2005
Advertisements

FDA Communications and Meetings
Participation Requirements for a Patient Representative.
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
Strengthening the Medical Device Clinical Trial Enterprise
510k Submission Overview Myraqa, Inc. August 22, 2012.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
FDA Pre-Submission Meetings for 510(k) Submissions
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21,
Special Topics in IND Regulation
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
Meetings with FDA Martha A. Feldman, RAC
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
Associate Director for Review Management
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Office of Clinical Research and Innovative Care Compliance (OCRICC) What You Need To Know About Conducting Research at Froedtert Hospital Roberta Navarro,
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Budget Development Presented by: Jean Mercer Associate Director for Clinical Research Administration Office of Clinical Research – School of Medicine.
Strategies for Preparing for Meetings with FDA Susan M. Mondabaugh, Ph.D. Vice President, Regulatory Affairs Hurley Consulting Associates Ltd. Chatham,
Mark A. Del Vecchio Director, Regulatory and Clinical Affairs Digene Corporation How to Work with FDA: Industry Perspective IVD Roundtable/OIVD Workshop.
New Draft Guidance for Multiplex Tests Elizabeth Mansfield and Michele Schoonmaker Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) CDRH/FDA.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Medical Device Consultants, Inc. Investing in a Clinical Program: Advice in a Challenging Economic Time MassMEDIC Medical Device Clinical Trials Update.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
June 23, 2005Abiomed, H DRAFT. CIRCULATORY SUPPORT DEVICES PANEL Thursday, June 23, 2005 Abiomed, Inc. Abiocor® Implantable Replacement Heart HDE.
1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
CMS and FDA’s Regulatory Review & Coverage Coordination
US FDA Pre-Submissions (Q Subs)
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
Device Updates in FDASIA MDUFA III RA SAIC – 9 th April 2013 Karen Jaffe, MS, MBA, RAC or
The Business Sales Process. 2 Our Business Sale Process - Overview Review Company’s operations and business plan Prepare and refine list of purchasers.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.
Drug Development Process Stages involved in Regulating Drugs
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
Strengthening the Medical Device Clinical Trial Enterprise
Clinical trials for medical devices: FDA and the IDE process
Rachel Neubrander, PhD Division of Cardiovascular Devices
Clinical Review Process for New Drug Development and Application
U.S. FDA Center for Devices and Radiological Health Update
Regulatory Considerations for Coronary Drug Coated Balloons (DCBs)
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
VenaSeal Closure System Utilization of the Pre-Submission Process & Interactive Review Sponsor’s Perspective 24 February 2015.
Pre-Investigational New Drug (pre-IND) Meeting with FDA
FDA’s IDE Decisions and Communications
How to Put Together an IDE Application
Director, Asia Pacific Japan and U.S. Clinical Operations
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
The FDA Early Feasibility Study Pilot and the Innovation Pathway
The Current PMA Requirements
First-in-Man, First In The USA: What’s The Difference?
Deputy Director, Division of Biostatistics No Conflict of Interest
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Benefits of US EFS: A Clinical Perspective
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
FDA-CDRH in the Next Decade A Vision for Change
FDA Center for Biologics Evaluation and Research (CBER) INitial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) Meetings *Audio.
Presentation transcript:

Understanding the Pre-IDE Program: FDA Perspective CAPT Stephen P. Rhodes, USPHS Director, IDE and HDE Programs Office of Device Evaluation AdvaMed AudioConference October 17, 2007 Stephen Rhodes, AdvaMed, October 2007

Collaboration with regulated industry are integral to our mission Committed to communicating and interacting with our stakeholders ODE/OIVD have 400+ meetings/year Average 80 meetings per division: 2 meetings/wk/division (not including teleconferences) FDAMA (1997): Early Collaboration meetings became regulation (Agreement, Determination meetings) AdvaMed October 17, 2005 -- PreIDEs

Why Pre-Submission Discussions? Benefits (to sponsors and FDA) Design testing and development plans that will expedite review and approval Save money and time More collaborative approach Minimize surprises Cost (to sponsors and FDA) Time and effort Money AdvaMed October 17, 2005 -- PreIDEs

Advice may be requested at any of these points in premarket phase: Prior to conducting “proof of concept” animal studies Preclinical Prior to expanding clinical trials from feasibility to pivotal phase Pre-PMA Day 100 PMA meetings Post-deficiency letter for 510(k) or PMA Appeal a final decision on a PMA or 510(k) or an IDE disapproval Agreement or determination meeting AdvaMed October 17, 2005 -- PreIDEs

Prior to Proof of Concept Discuss concepts, broad outline of test plan, bench test methodologies (e.g., use of consensus standards, need for animal studies, need for clinical studies) Discuss possible regulatory pathways Discuss potential combination product issues Face-to-face meetings are usually not held at this stage (premature). AdvaMed October 17, 2005 -- PreIDEs

AdvaMed October 17, 2005 -- PreIDEs Preclinical phase Prototype evaluated in preliminary animal models Proposed clinical application (possibly not specific patient population) and indication for use FDA feedback on: Bench testing plan – methods, standards Animal study protocols Feasibility study protocols Preliminary guidance on SR/NSR (need for IDE) Preliminary (non-binding) guidance on regulatory pathway Feedback dependent on focused questions PreIDE meetings/teleconferences encouraged at this stage AdvaMed October 17, 2005 -- PreIDEs

Prior to initiating pivotal trials Feasibility studies completed (or nearly so) Device design finalized to extent possible Animal studies completed (or in follow-up) Pivotal trial protocol “fleshed out” (including 1º and 2º endpoints, duration, evaluation methods, statistical analysis) Specific indication for use (and patient population) determined AdvaMed October 17, 2005 -- PreIDEs

Prior to initiating pivotal trials (cont.) FDA will give feedback on: Need for further bench/animal studies Need for pilot study prior to initiating pivotal study Proposed pivotal study protocol: endpoints, duration, evaluation, statistical analysis plan Proposed regulatory pathway Proposed indication for use Preliminary nonbinding feedback on expedited status, need for advisory panel meeting Feedback dependent on focused questions Meetings/teleconferences with FDA encouraged at this stage AdvaMed October 17, 2005 -- PreIDEs Stephen Rhodes, AdvaMed, October 2007

AdvaMed October 17, 2005 -- PreIDEs Scheduling informal pre-IDE meetings (not determination or agreement meetings) Planning/scheduling may be done by project manager (usually 3-4 weeks after preIDE received) Complete pre-meeting package needed before meeting will be scheduled Divisions may have checklists/other guidelines for what is expected in pre-meeting package: Check! Expect meeting to be cancelled/postponed if extensive new information submitted after meeting scheduled AdvaMed October 17, 2005 -- PreIDEs

Pre-IDEs: What they are and what they are not Tool to provide informal feedback on: Preclinical test plan Clinical/statistical test plan NSR/Exempt investigations OUS investigations NOT intended to be: A tool for negotiation An iterative process Modular review Review of data (“pre-510(k)”, “pre-PMA”) As in depth as an IDE or marketing application review Legally binding Method for dispute resolution AdvaMed October 17, 2005 -- PreIDEs

AdvaMed October 17, 2005 -- PreIDEs Recommendations FDA is doing our homework before your meeting; please do yours! Think carefully about what you want to get from a meeting – are you ready to talk with FDA? If you must make changes to device or protocol after pre-IDE package has been submitted, be prepared to cancel and reschedule Manage your meeting time carefully Bring right people to discuss focused questions Ask for clarification AdvaMed October 17, 2005 -- PreIDEs

AdvaMed October 17, 2005 -- PreIDEs Recommendations Do not expect FDA to: Make guarantees or binding commitments (unless it is a determination or agreement meeting) Approve study or clear/approve device at meeting Act as a consultant Give special treatment or favors Hold to informal feedback provided years ago – technology does not stay constant Have a series of meetings on the same topics – make the most of THIS meeting AdvaMed October 17, 2005 -- PreIDEs

AdvaMed October 17, 2005 -- PreIDEs More Information October 10, 2007 Federal Register Notice: List of Guidance Documents under review in CDRH Pre-PMA and Pre-IDE Meetings http://www.fda.gov/cdrh/mdufma/guidance/agenda/fy08.html CDRH Website: Device Advice http://www.fda.gov/cdrh/devadvice/ AdvaMed October 17, 2005 -- PreIDEs Stephen Rhodes, AdvaMed, October 2007